{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosiglitazone",
    "query": {
      "intervention": "Rosiglitazone"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 110,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosiglitazone&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T10:13:13.844Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00413335",
      "title": "Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Impaired Glucose Tolerance",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 21,
      "start_date": "2005-11",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2013-07-22",
      "last_synced_at": "2026-09-02T10:13:13.844Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00413335"
    },
    {
      "nct_id": "NCT00814255",
      "title": "Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Segmental Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Lisinopril, losartan, and atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "galactose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "1 Year to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2008-12",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2016-07-11",
      "last_synced_at": "2026-09-02T10:13:13.844Z",
      "location_count": 17,
      "location_summary": "Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00814255"
    },
    {
      "nct_id": "NCT00428090",
      "title": "Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 862,
      "start_date": "2007-02-27",
      "completion_date": "2008-09-05",
      "has_results": true,
      "last_update_posted_date": "2017-05-19",
      "last_synced_at": "2026-09-02T10:13:13.844Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 34 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Reseda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00428090"
    },
    {
      "nct_id": "NCT00130286",
      "title": "Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV-Associated Lipodystrophy Syndrome",
        "Insulin Resistance",
        "HIV Infections",
        "Metabolic Syndrome X",
        "Body Weight Changes"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human growth hormone + rosiglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 77,
      "start_date": "2005-03",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2014-02-13",
      "last_synced_at": "2026-09-02T10:13:13.844Z",
      "location_count": 4,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00130286"
    },
    {
      "nct_id": "NCT00099918",
      "title": "Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "vildagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 717,
      "start_date": "2004-05",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2017-05-17",
      "last_synced_at": "2026-09-02T10:13:13.844Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099918"
    },
    {
      "nct_id": "NCT00348140",
      "title": "Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone Extended Release 2mg",
          "type": "DRUG"
        },
        {
          "name": "Rosiglitazone Extended Release 8mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 1468,
      "start_date": "2006-07-12",
      "completion_date": "2009-03-20",
      "has_results": true,
      "last_update_posted_date": "2017-09-05",
      "last_synced_at": "2026-09-02T10:13:13.844Z",
      "location_count": 49,
      "location_summary": "Sun City, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00348140"
    },
    {
      "nct_id": "NCT00193648",
      "title": "Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Focal Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone (Avandia)",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab (Humira)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "2 Years to 40 Years"
      },
      "enrollment_count": 21,
      "start_date": "2005-07",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2007-10-22",
      "last_synced_at": "2026-09-02T10:13:13.844Z",
      "location_count": 2,
      "location_summary": "New Hyde Park, New York • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00193648"
    },
    {
      "nct_id": "NCT00242593",
      "title": "Rosiglitazone Effects on Cognition for Adults in Later Life",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2006-06",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2011-08-05",
      "last_synced_at": "2026-09-02T10:13:13.844Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Seattle/Tacoma, Washington",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Seattle/Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00242593"
    },
    {
      "nct_id": "NCT00567593",
      "title": "Gene Regulation by Thiazolidinediones",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Inflammatory Bowel Disease"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "James Lewis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 12,
      "start_date": "2007-10",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2016-08-01",
      "last_synced_at": "2026-09-02T10:13:13.844Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00567593"
    },
    {
      "nct_id": "NCT00178841",
      "title": "Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous T-cell Lymphoma",
        "Mycosis Fungoides",
        "Sezary Syndrome"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone and Bexarotene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2005-06",
      "completion_date": "2007-03",
      "has_results": true,
      "last_update_posted_date": "2016-02-17",
      "last_synced_at": "2026-09-02T10:13:13.844Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00178841"
    }
  ]
}